anonymous
Guest
anonymous
Guest
Bottom line the focus is off of Arista and it continues to loose market share. The loss of contracts and the lack of focus in this area has become an issue for Arista. There is no way Progel will compete due to cost and our buyers are becoming much more cost conscious. You can get all the VATS and Dural indications you want but it won't gain much traction.
Any truth to this ?